NCT05497297View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

October 23, 2022

Study Completion Date

October 26, 2022

Conditions

Renal Impairment

Interventions

DRUG

HSK7653 tablets

HSK7653, tablet, oral

Trial Locations (1)

Unknown

Beijing Jishuitan Hospital, Beijing

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY